Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Phase: Phase 1/Phase 2
Diagnosis: Breast: Metastatic
NCT ID: NCT02041429
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-494
This phase I/II research study is evaluating a combination of drugs called paclitaxel and ruxolitinib as a possible treatment for inflammatory breast cancer. Ruxolitinib is a newly discovered drug that has been shown to block a pathway (called the IL6/JAK/Stat pathway) that may be important in cancer, including breast cancer. Blocking this pathway may stop cancer cells from growing. Ruxolitinib has been approved by the FDA for patients with bone marrow disease, and this is the first study using this drug in combination with paclitaxel for breast cancer. Paclitaxel (also called Taxol) is an FDA drug approved for breast cancer patients. Paclitaxel works by blocking the small microtubules inside cancer cells and preventing cell growth. Information from laboratory experiments suggests that ruxolitinib might also have effects on breast cancer.These studies have shown that ruxolitinib may make paclitaxel more effective.
Dana-Farber Cancer Institute, Brigham and Women's Hospital
Beth Overmoyer, MD,
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478
- Participants must meet the following criteria on screening examination to be eligible
to participate in the study:
- Participants must have histologically confirmed breast cancer that is metastatic or
unresectable and for which standard curative or palliative measures do not exist or
are no longer effective.
- Patients may not have received > 2 prior chemotherapies for advanced disease.
- Either measurable or evaluable disease is allowed.
- Age ≥18 years. Because no dosing or adverse event data are currently available on the
use of ruxolitinib in participants <18 years of age, children are excluded from this
- Life expectancy of greater than 3 months.
- ECOG performance status ≤ 2 (see Appendix A).
- Participants must have normal organ and marrow function as defined below:
- Leukocytes ≥3,000/mcL
- Absolute neutrophil count ≥1,500/mcL
- Platelets ≥100,000/mcL
- Total bilirubin within normal institutional limits
- AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal
- Creatinine within normal institutional limits or creatinine clearance ≥ 60
mL/min/1.73 m2 for subjects with creatinine levels about institutional normal
- Both men and women are allowed.
- The effects of ruxolitinib on the developing human fetus are unknown. For this reason
women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation. Should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
- Ability to understand and the willingness to sign a written informed consent
- Participants who exhibit any of the following conditions at screening will not be
eligible for admission into the study.
- Participants may not be receiving any other study agents within 2 weeks of initiating
- Participants with untreated or uncontrolled brain metastases are excluded from this
clinical trial. Patients with treated and stable (> 4 weeks) brain metastasis are
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to ruxolitinib.
- Participants receiving any medications or substances that are strong inhibitors of
CYP3A4 are ineligible. (Please refer to Appendix B for list and washout periods).
- Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once
- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
- Pregnant women are excluded from this study because ruxolitinib is a JAK inhibitor
with the potential for teratogenic or abortifacient effects. Because there is an
unknown but potential risk of adverse events in nursing infants secondary to
treatment of the mother with ruxolitinib, breastfeeding should be discontinued if the
mother is treated with ruxolitinib. These potential risks may also apply to other
agents used in this study.
- Individuals with a history of a different malignancy are ineligible except for the
following circumstances. Individuals with a history of other malignancies are
eligible if they have been disease-free for at least 3 years and are deemed by the
investigator to be at low risk for recurrence of that malignancy. Individuals with
the following cancers are eligible if diagnosed and treated within the past 3 years:
cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
- Clinically significant malabsorption syndrome.
- Prior chemotherapy or radiation administered within 2 weeks from initiating study